This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Tries to Quell Fears About MS Drug Rivals

Biogen Idec (BIIB - Get Report) gathered investors together Wednesday to pitch the company's research pipeline and stifle concerns that its leading position in the multiple sclerosis treatment market was vulnerable to competition.

A phase III study of a long-acting version of Avonex, the company's top-selling multiple sclerosis drug, will begin in the middle of the year, the company announced. The drug, called PEG-Avonex, aims to be more convenient than but equally effective as Avonex, Biogen Idec's most important drug with $2.2 billion in sales last year.

Multiple sclerosis patients will take PEG-Avonex by injection every two weeks or every four weeks instead of the weekly injection required for Avonex.

Biogen Idec also said that patient enrollment has completed in the first of two phase III studies of the company's oral multiple sclerosis drug known as BG-12.

Both BG-12 and PEG-Avonex are important for Biogen Idec's future growth because of competition from Novartis (NVS - Get Report) and the German drug maker Merck KGaA, which are developing oral multiple sclerosis drugs of their own.

Both the Novartis drug, known as FTY720, and the Merck drug, cladribine, have posted positive results in phase III studies, and both companies have already announced plans to seek regulatory approval later this year.

All current multiple sclerosis drugs, including Biogen's Avonex and Tysabri, which it co-markets with Elan (ELN), are administered by injections, which leaves them commercially vulnerable to an oral multiple sclerosis drug, if one can be approved that is equally or more effective with an acceptable safety profile.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
BIIB $303.69 0.00%
NVS $98.35 0.00%
AAPL $113.29 0.00%
FB $91.01 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs